← Back to Search

Janus Kinase (JAK) Inhibitor

Deucravacitinib for Plaque Psoriasis

Phase 3
Recruiting
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Moderate to severe disease
Plaque psoriasis for at least 6 months
Must not have
Prior exposure to deucravacitinib (BMS-986165) or active comparator
Participants weighing ≤ 30.0 kg at screening for Cohort 1 (age 12 to < 18 years), Part A and Part B. Participants weighing ≤ 13.0 kg at screening for Cohort 2 (age 4 to < 12 years), Part A and Part B.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 466 days
Awards & highlights

Summary

This trial is testing a new drug for plaque psoriasis in adolescents to see if it is safe and effective. The first part will test different doses to see what levels of the drug are safe and effective. The second part will test the long-term safety of the drug.

Who is the study for?
This trial is for kids and teens aged 4 to <18 with moderate to severe plaque psoriasis. They should be candidates for phototherapy or systemic therapy, have had psoriasis for at least 6 months, and not weigh less than the set limits. Those with other psoriasis types, recent infections, TB, or prior deucravacitinib use can't join.
What is being tested?
The study tests Deucravacitinib's levels and effectiveness in young patients with plaque psoriasis. It has two parts: Part A finds the right doses; Part B checks how well these doses work. There's also a long-term part that looks at safety over five years.
What are the potential side effects?
While specific side effects aren't listed here, common ones from drugs like Deucravacitinib may include liver issues, infections due to immune system effects, headaches, nausea, and possible allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My condition is moderate to severe.
Select...
I have had plaque psoriasis for at least 6 months.
Select...
I am between 12 and 17 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have previously been treated with deucravacitinib.
Select...
I weigh ≤ 30.0 kg and am aged 12-17, or weigh ≤ 13.0 kg and am aged 4-11.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 466 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 466 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Geometric mean observed average concentration at steady state (Cavg.ss) for deucravacitinib at Week 2
Maximum observed plasma concentration at steady state (Cmax.ss) for deucravacitinib at Week 2
Proportion of subjects with an static Physician's Global Assessment (sPGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point reduction from baseline at Week 16
+2 more
Secondary outcome measures
Change from baseline in BSA involvement at Week 16 for comparison of deucravacitinib vs placebo
Change from baseline in CDLQI score at Week 16 for comparison of deucravacitinib vs placebo
Change from baseline in PASI at Week 16 for comparison of deucravacitinib vs placebo
+35 more

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Active treatment deucravacitinib standard doseExperimental Treatment1 Intervention
Group II: Active treatment deucravacitinib half-standard doseExperimental Treatment1 Intervention
Group III: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Deucravacitinib
2021
Completed Phase 4
~160

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,677 Previous Clinical Trials
4,126,812 Total Patients Enrolled

Media Library

Deucravacitinib (Janus Kinase (JAK) Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04772079 — Phase 3
Plaque Psoriasis Research Study Groups: Active treatment deucravacitinib standard dose, Active treatment deucravacitinib half-standard dose, Placebo
Plaque Psoriasis Clinical Trial 2023: Deucravacitinib Highlights & Side Effects. Trial Name: NCT04772079 — Phase 3
Deucravacitinib (Janus Kinase (JAK) Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04772079 — Phase 3
~84 spots leftby Jan 2029
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top